Kornimate/medical-research-clean huggingface dataset:
postoperative pain control for prostatectomy

Conditions: Prostate Cancer

Summary: the researchers propose to investigate a relatively new anesthetic procedure, in order to maximize patient comfort and minimize the use of narcotics after a radical prostatectomy.

our current post operative analgesic strategy involves a multi-modal approach, using local injectable anesthetic around the incision and systemic medications (i.e. non-steroidal anti-inflammatories, acetaminophen and break-through doses of opiates). as the amount of opiates used can be significant, we have to be aware of their inherent risks. opiates have an excellent pain control profile, working peripherally by decreasing the amount of neurotransmitters released from neurons involving noxious stimuli, and also in their central processing. some of the more common adverse reactions are reparatory depression, sedation, confusion, delirium, nausea, pruritis, constipation, hypotension and bradycardia. often it is these resulting side effects that extend the length of in hospital rehabilitation, and decrease a patient's overall satisfaction. thus we propose the use of a relatively new regional anesthetic technique be employed to further decrease the need for opiates in our prostatectomy patients' post-op course, while adequately controlling their pain.

Eligibility criteria:
inclusion criteria: * prostate cancer for radical prostatectomy exclusion criteria: * chronic pain or opiate use

Keywords: radical prostatectomy
dexmedetomidine and pregabalin for conscious sedation during cataract surgery

Conditions: Conscious Sedation

Summary: although topical anesthesia by eye drops for cataract surgery is a non-invasive technique but it may provide insufficient anesthesia which requires the intraoperative use of additional topical local anesthetics and raises the need for sedation.

the present study is constructed to evaluate the effect of pregabalin on sedation using dexmedetomidine for cataract surgery under topical anesthesia . in the dexmedetomidine-pregabalin group, the patients will be premedicated by pregabalin. in the placebo group (control group) the patients will be premedicated by placebo capsules. all patients will be sedated by dexmedetomidine. sedation will be assessed as a primary outcome measurement where pain, vital signs, intraoperative and postoperative pain, total analgesic needs and side effects will be assessed as secondary outcome measurements.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) i and ii physical status. * scheduled for cataract extraction under topical anesthesia. exclusion criteria: * hepatic or renal impairment. * taking chronic psychotropic medications. * mental instability. * morbid obesity. * alcohol abuse. * substance abuse. * pregnant and lactating females. * history of allergy to the study drugs used
statin therapy versus placebo prior to prostatectomy

Conditions: Cancer; Prostate Cancer

Summary: this is a randomized trial comparing the effect of oral simvastatin versus placebo on targets of the mevalonate pathway in men undergoing a prostatectomy as planned management for prostate cancer. observed tissue effects will be correlated with changes in serum cholesterol and low-density lipoprotein.

prostate cancer patients that have chosen to undergo a prostatectomy as their primary treatment option will be recruited to this trial. forty-four subjects will be randomized to either placebo or simvastatin (40 mg po/day) for 4 weeks prior to surgery. serum samples will be obtained at baseline and immediately prior to prostatectomy. at prostatectomy, cancerous and benign prostate tissue will be microdissected and cryopreserved. archival prostatectomy tissues will be used to construct tissue microarrays containing matched benign and malignant sections. the effect of hmg-coa reductase inhibition on lipid raft cholesterol content and targets of prenylation will be determined. the incidence of apoptosis will be determined along with protein levels of mediators of apoptosis. lastly the effect of statin therapy on cellular markers of proliferation will be determined. previously, we studied the effect of statin use on the risk of prostate cancer detection in a case-control study at the portland va medical center. statin use was associated with a 62% reduction in cancer odds-risk (or = 0.38, 95% ci 0.21-0.69). although these epidemiologic and laboratory findings have generated enthusiasm for the study of statins in prostate cancer, no studies have examined the biologic effects of statins on prostate cancer in humans. hypothesis: statin therapy prior to prostatectomy will successfully target the mevalonate pathway in the human prostate and this intervention will favorably alter tumor biomarker status.

Eligibility criteria:
inclusion criteria: * histologically confirmed prostatic adenocarcinoma with gleason 5 to 7 (3+4 = 7 accepted, not 4 + 3 = 7) * radical prostatectomy chosen as primary treatment for prostate cancer * age 18 years or older * eastern cooperative oncology group (ecog) performance status of 0 or 1 exclusion criteria: * other preoperative or prior treatment directed at prostate cancer (i.e., radiation, hormonal therapy, cryotherapy) * significant active medical illness which in the opinion of the investigator would preclude protocol treatment * history of or active liver disease or abnormal results of the baseline liver function test (\> 2 x normal) * current use of: * simvastatin * lovastatin * other hmg-coa inhibitors * lipid-lowering agents * amiodarone * cholestyramine * cholestyramine and colestipol (bile acid sequestrants) * clofibrate and fenofibrate * cyclosporine * cyp3a4 inhibitors * danazol * diltiazem * gemfibrozil * niacin ( 1 g/day) * verapamil and warfarin * known allergy or sensitivity to ingredients in simvastatin

Keywords: cancer pre-operative surgery prostate prostatectomy radiation
a study of efficacy, safety and tolerability of idebenone in the treatment of friedreich's ataxia (frda) patients

Conditions: Friedreich's Ataxia

Summary: the purpose of this trial is to study the efficacy, safety and tolerability of idebenone in 12 months of treatment in children and adults with friedreich's ataxia. this is a randomised placebo-controlled double-blind trial conducted in europe. efficacy outcomes include measures of neurological impairment and function, and measures of the heart.

idebenone, a short-chain analogue of co-enzyme q10 (coq10), has the potential to moderate underlying causes of friedreich's ataxia through its antioxidant activity and its role as an electron carrier in the respiratory chain promoting mitochondrial atp production. the current 12-month placebo-controlled treatment study in 232 patients aims to confirm the positive effect of idebenone on neurological function, as for instance observed in the recent 48-patient, 6-month nicosia study in children, using the international cooperative ataxia rating scale (icars) and the newly developed friedreich's ataxia rating scale (fars). in addition, the study aims to confirm the positive effect on cardiomyopathy associated with frda observed in several small studies. cardiac anatomy and function will be assessed using echocardiography, tissue doppler imaging and cardiac mri methods in patients with frda cardiomyopathy. in addition exercise capacity, measured as peak workload, will be assessed in patients able to comply with a modified exercise protocol.

Eligibility criteria:
inclusion criteria: * documented diagnosis of frda with confirmed frda mutations * patients 8 years of age or older at baseline * patients with body weight ≥ 25kg * patients who in the opinion of the investigator are able to comply with the requirements of the study, including swallowing the medication * negative urine pregnancy test at screening and at baseline (women of childbearing potential) exclusion criteria: * treatment with idebenone or coenzyme q10 within the past 1 month * pregnancy and/or breast-feeding * clinically significant abnormalities of clinical haematology or biochemistry including, but not limited to, elevations greater than 1.5 times the upper limit of normal of sgot, sgpt, or creatinine * past or present history of abuse of drugs or alcohol

Keywords: frda idebenone frda disease
pen-administered low-dose dasiglucagon for prevention and treatment of hypoglycemia in people with type 1 diabetes

Conditions: Type 1 Diabetes; Hypoglycemia

Summary: the aim of the study is to evaluate the efficacy, safety and feasibility of outpatient-utilization of low-dose dasiglucagon administered via a multi-dose reusable pen injector in preventing and treating mild hypoglycemia in insulin pump-treated people with type 1 diabetes.

a randomized, open-label, two-arm, two-week crossover study will be conducted to assess the study objectives. the study will enroll 24 participants with insulin pump-treated type 1 diabetes. upon study enrollment, participants will complete two consecutive 2-week periods - a 'usual care' period and 'dasiglucagon' period. during the 'usual care' period, participants will manage episodes of manifest or impending hypoglycemia as usual, e.g. through carbohydrate consumption or manual insulin pump suspension. during the 'dasiglucagon' period, participants will use pen-administered low-dose dasiglucagon to treat or prevent episodes of hypoglycemia.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * t1d ≥ 2 years * use of insulin pump therapy (without sensor-augmented insulin suspension/adjustment functionality) ≥ 6 months * use of cgm (real-time or intermittently scanned) ≥ 3 months and ≥ 70% during the previous 14 days * hba1c ≤ 70 mmol/l (8.5%) * performs aerobic exercise on a regular basis (≥ 2 times per week; self-reported) and desires to exercise per american diabetes association guidelines (150 minutes per week) during the study. * use of carbohydrate counting and bolus calculator (self-reported) * sensor glucose level \< 3.9 mmol/l on ≥ 4/14 previous days assessed by cgm data exclusion criteria: * use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during the study period and within 30 days prior to study start * known or suspected allergies to glucagon or related products * history of hypersensitivity or allergic reaction to dasiglucagon or any of the excipients * patients with pheochromocytoma or insulinoma * hypoglycemia unawareness * females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods * inability to understand the individual information and to give informed consent * current participation in another clinical trial that, in the judgment of the investigator, will compromise the results of the study or the safety of the subject * concomitant medical or psychological conditions identified through review of medical history, physical examination and clinical laboratory analysis that, according to the investigator's assessment, makes the individual unsuitable for study participation

Keywords: type 1 diabetes hypoglycemia dasiglucagon
effects of traditional greek meals on glycemic responses

Conditions: Potential Abnormality of Glucose Tolerance; Appetitive Behavior

Summary: this study investigated the effects of greek traditional meals in dehydrated form consumed after reconstitution with water on glycemic responses

this study aimed at 1. to determined the glycemic index and glycemic load of three mixed meals and 2. to investigate the effects of these mixed meals on postprandial glycemic response in healthy subjects

Eligibility criteria:
inclusion criteria: * healthy * non-smoking * non-diabetic men and women * normal body mass index (bmi; between 18.5 and 25 kg/m2) exclusion criteria: * severe chronic disease (e.g. coronary heart disease, diabetes mellitus, kidney or liver conditions, endocrine conditions) * gastrointestinal disorders * pregnancy * lactation * competitive sports * alcohol * drug dependency

Keywords: blood glucose lentils trahanas halva glycemic index
androgen receptor mrna expression is positively associated with live birth in women undergoing ivf independently of the type of ovarian response

Conditions: Androgen Receptor Gene Overexpression; Normal Responders; Poor Ovarian Response; Bologna Criteria

Summary: ar is a steroid hormone receptor that regulates various genes' expression and affects cellular proliferation and differentiation. androgens interact with ar, exert their paracrine action on granulosa cells and regulate gonadotropin synthesis, follicle development, oocyte maturation and corpus luteum function. estrogens increase ar mrna and testosterone binding site in uterine endometrium and leiomyoma. in human cancer cells, low estradiol increases ar levels, suggesting the estrogen/androgen ratio as a predictor of sex steroid response. ar mrna expression is, also, regulated by progesterone. although ar mrna is expressed in the female reproductive tissues, its expression has never been studied in peripheral blood.


Eligibility criteria:
inclusion criteria: * women with poor ovarian response according to bologna criteria 1. advanced maternal age (≥40 years) or any other risk factor for poor ovarian response 2. a previous poor ovarian response (≤3 oocytes with a conventional stimulation protocol) 3. abnormal ovarian reserve test, (afc ˂5-7 follicles or amh ˂0.5-1.1 ng/ml). * women with normal ovarian response with normal menstrual cycles, normal astral follicle count and normal hormonal assay. exclusion criteria: * not more than 43 years old. * no history of malignancies, endometriosis or polycystic ovary syndrome. * underlying genetic cause of infertility * history of severe cardiac, hepatic or renal disease. * history of systemic disease or treatment during the last three (3) months * participation in another interventional study and a likelihood of being unavailable for follow-up.
assessment of urinary diversions outcomes post radical cystectomy in asyut university urology hospital

Conditions: Bladder Cancer

Summary: radical cystectomy (rc) for bladder cancer requires reconstruction of the lower urinary tract. both continent and incontinent diversions are available for urinary reconstruction after rc. types of urinary diversions include ( ileal conduit, uretero-cutaneous, ureterosigmoidostomy and orthotopic bladder) the decision process is complex and involves consideration of issues related to cancer stage, patient comorbidities, treatment needs, and patient desires related to quality of life and intraoperative findings. outcomes of urinary diversions include 1- survival rate (cancer specific or overall survival). 2- oncological failure (local, distant or lns). 3- complications (perioperative, intraoperative or post-operative). in this study, all these outcomes will be analyzed.


Eligibility criteria:
inclusion criteria: * \* all patients underwent radical cystectomy more than 1 year exclusion criteria: * incomplete data * patients underwent rc outside urology department and presented for treatment of complications.
study to evaluate the effect of gbt440 administered to subjects with ipf on supplemental oxygen at rest

Conditions: Idiopathic Pulmonary Fibrosis; Hypoxemia

Summary: this is an open label study in which eligible ipf subjects who are using supplemental oxygen at rest will receive gbt440 orally daily.


Eligibility criteria:
inclusion criteria: * documented diagnosis of ipf. * receiving supplemental oxygen for use at rest. * weight ≥ 40 kg. * male or female of child bearing potential willing and able to use highly effective methods of contraception from study start to 30 days after the last dose of study drug. exclusion criteria: * fev1/fvc \< 70% * history of other interstitial lung diseases. * subject plans to begin or has commenced pulmonary rehabilitation within 30 days of screening. * corticosteroid (\> 10 mg per day of prednisone or an equivalent) administered for 7 days or longer, within 30 days of screening. * participated in another clinical trial of an investigational drug (or medical device) within 30 days or 5-half-lives, whichever is longer, prior to screening, or is currently participating in another trial of an investigational drug (or medical device). * female who is breast-feeding or pregnant * current smoker or history of smoking within 3 months from screening

Keywords: idiopathic pulmonary fibrosis hypoxemia oxygen
alzheimer's disease acitretin medication

Conditions: Alzheimer Disease

Summary: the trials investigates the changes of cerebral spinal fluid (csf) soluble alpha-secretase cleaved app (appsα) levels under oral therapy with acitretin 30mg daily in patients with mild to moderate alzheimer's disease (ad).the present study aims to demonstrate an enhancement of the α-secretase activity by acitretin as measured by increased csf appsα levels in human ad. second, the safety and tolerability of acitretin in ad patients should be proven.


Eligibility criteria:
inclusion criteria: * mild to moderate ad (nincds-adrda criteria) * mini-mental state examination (mmse): 27-14 points * geriatric depression scale ≤ 14 exclusion criteria: * hereditary cognitive impairment * known history of brain injuries * insufficient german language skills * actual treatment with other potential disease modifying drugs of ad * multimorbidity or significant organ (esp. liver or renal) dysfunction * evidence of non-ad neurodegenerative disorder (e.g. parkinson) * contraindication to acitretin such as osteoporosis, hypoalbuminaemia

Keywords: alzheimer's disease
intercostal liposomal bupivacaine for the management of blunt chest wall trauma

Conditions: Blunt Chest Wall Trauma; Rib Fracture; Sternal Fracture

Summary: this is a study of liposomal bupivacaine for pain control in patients with blunt chest wall trauma.

the purpose of this study is to evaluate the efficacy of liposomal bupivacaine to provide analgesia via paravertebral intercostal nerve block following significant blunt chest trauma, minimizing adverse outcomes, length of stay and overall narcotic use. the primary outcome of the study is to compare requirements between the bupivacaine group and a standard-of-care group.

Eligibility criteria:
inclusion criteria: * anticipated length of stay of at least 72 hours * blunt chest wall trauma with two or more rib or sternal fractures * demonstrated ability to achieve \> 50% predicted inspiratory capacity based on ideal body weight using is within the first 24 hours of admission exclusion criteria: * known allergy to bupivacaine * respiratory failure requiring intubation within 24 hours prior to enrollment * known or suspected atrioventricular nodal blockade process requiring cardiology evaluation or pacemaker placement * hemodynamic instability (defined as new intravenous vasopressor or inotrope requirement or mean arterial pressure \< 55 mmhg) * signs of active myocardial ischemia or non-st elevation mi * \> 20 rib fractures * weight \ 150 kg * pregnancy * incarceration
mrd-guided prognosis prediction and adjuvant treatment based on ctc and ctdna in nsclc

Conditions: Non-small Cell Lung Cancer

Summary: this is a prospective cohort study, which aims to evaluate the effectiveness and superiority of a novel minimal residual disease-guided prognosis monitoring and adjuvant treatment in stage iia-iiic non-small cell lung cancer.

this observational study is a single-center, prospective cohort study, which aims to detect minimal residual disease (mrd) using circulating tumor cells (ctc) and circulating tumor dna (ctdna). to evaluate the effectiveness and superiority of mrd detection, we enroll operable or inoperable iia-iiic stage nsclc patients, and single-cell rna sequencing and genomic sequencing would be performed for ctc and ctdna, respectively.

Eligibility criteria:
inclusion criteria: 1. written informed consent must be signed before implementing any enrollment-related procedures; 2. age ≥18 years old; 3. patients with histologically or cytologically confirmed stage iia-iiic nsclc (international association for the study of lung cancer and american joint committee on classification of cancer, 8th edition tnm staging)； 4. there is no special restriction on the source of genetic test report. 5. according to the response evaluation criteria in solid tumors (recist, version 1.1), there is at least one radiographically measurable lesion. 6. have not received any previous systemic antitumor therapy for advanced diseases. 7. no serious abnormalities of hematopoietic function, heart, lung, liver, kidney function and immune system. 8. ecog score: 0-1; 9. expected survival time \> 3 months. exclusion criteria: 1. received surgical treatment for lung tumors. 2. received neoadjuvant chemotherapy or radiotherapy. 3. received cellular therapy within the last 1 year. 4. treated but uncontrolled diabetes, mellitus, asthma, autoimmune diseases and other chronic diseases. 5. participated in other clinical trials (including research vaccines, drugs, medical devices, etc.) within one month.

Keywords: nsclc minimal residual disease prognosis monitoring adjuvant treatment
rnfl thickness measurements obtained using sd-oct and slp using gdx variable corneal compensation

Conditions: Uveitis

Summary: the aim of this study is to evaluate the correlation of retinal nerve fiber layer (rnfl) thickness measured using spectral domain optical coherence tomography (sd-oct) and scanning laser polarimetry (slp) in uveitic eyes compared to healthy eyes. a descriptive, observational, prospective, consecutive, cross-sectional, controlled, mono-center case series was conducted from may to october 2015. clinical characteristics, best-corrected visual acuity, intra-ocular pressure, rnfl thickness measurement with sd-oct and slp using gdx variable corneal compensation (gdx vcc) were performed for each patient. an evaluation of anterior chamber inflammation with laser flare cell meter was also carried out. correlations between sd-oct and gdx vcc rnfl measurement were evaluated by linear regression analysis.


Eligibility criteria:
inclusion criteria: * age ≥18 years, * best-corrected visual acuity better than or equal to 20/40, * spherical refraction between -6.00 and +3.00 diopters, * no retinal disease or non-glaucomatous neuropathy, and no ophthalmic surgery in the past 6 months. exclusion criteria: * healthy eye were excluded in case of consecutive and reliable abnormal standard automated perimetry with abnormal glaucoma hemifield test and pattern standard deviation outside 95% of normal limits, and optic nerve damage (asymmetric cup-to-disc ratio ≥ 0.2, rim thinning, notching, excavation, or retinal nerve fiber layer defect). * any history of ophthalmic disease.

Keywords: retinal nerve fiber layer thickness uveitis sd-oct gdx vcc